Defined and Scalable Generation of Hepatocyte-like Cells from Human Pluripotent Stem Cells
March 2nd, 2017
The method presented here describes a scalable and good manufacturing practice (GMP)-ready differentiation system to generate human hepatocyte-like cells from pluripotent stem cells. It serves as a cost-effective and standardized system to generate human hepatocyte-like cells for basic and applied human liver research.
The overall goal of this protocol is to produce human hepatocyte-like cells from pluripotent stem cells using recombinant laminin matrices under defined conditions.This method allows the user to custom-make functional human hepatocytes to study liver biology in the dish.The main advantage of this technique is that its defined nature allows mass production of hepatocytes with high degree of experimental reproducibility.To begin the experiment thaw 100 microgram per milliliter stock of recombinant laminin-521, or LN-521, at four degrees Celsius.Dilute the thawed LN-521 in ice cold 1xDBPS with calcium magnesium to make a five microgram per milliliter solution.Add one milliliter of the five microgram per milliliter LN-521 solution to coat one well of a six well plate, and rock the plate to spread it evenly in the well.Next, incubate the plates in a 37 degree Celsius 5%CO2 cell culture incubator for at least two hours for urgent use.Take the coated plate from the incubator to the tissue culture hood.Carefully aspirate the coating LN-521 solution without damaging the coated surface.Then immediately add one milliliter of pre-warmed mTeSR
Overview
This protocol outlines a method to generate human hepatocyte-like cells from pluripotent stem cells using recombinant laminin matrices. It provides a scalable and GMP-ready system for producing functional hepatocytes for liver research.
Key Study Components
Area of Science
- Cell differentiation
- Stem cell biology
- Liver research
Background
- Human hepatocyte-like cells are crucial for studying liver biology.
- Pluripotent stem cells can differentiate into various cell types.
- Recombinant laminin matrices support cell adhesion and growth.
- Standardized methods enhance reproducibility in research.
Purpose of Study
- To develop a cost-effective method for producing hepatocyte-like cells.
- To enable mass production of functional hepatocytes.
- To facilitate research in liver biology and disease modeling.
Methods Used
- Thawing and diluting recombinant laminin-521.
- Coating cell culture plates with laminin solution.
- Incubating plates to promote cell adhesion.
- Adding pre-warmed mTeSR for cell culture.
Main Results
- Successful generation of human hepatocyte-like cells.
- High reproducibility of cell production.
- Functional characteristics of hepatocyte-like cells confirmed.
- Scalable system suitable for various research applications.
Conclusions
- The method provides a reliable approach to hepatocyte production.
- It supports both basic and applied liver research.
- Future studies can leverage this system for drug testing and disease modeling.
Frequently Asked Questions
Executive Industry Relevance
Defined differentiation systems reduce batch variability in hepatocyte-like cell production, enhancing reproducibility for preclinical liver models. Scalable, GMP-compatible processes support consistent supply for drug metabolism and toxicity testing. This addresses a key bottleneck in translating stem cell-derived hepatocytes to industrial applications.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of hepatic pathways using physiologically relevant, scalable cell models.
- Operational Value: Defined laminin matrices minimize variability, improving assay consistency across experiments.
- Predictive Value: High reproducibility supports reliable target engagement and mechanism-of-action studies.
Screening & Assay Development
- Scientific Value: Produces hepatocyte-like cells with stable metabolic function for compound screening.
- Operational Value: Serum-free, defined conditions allow standardization across laboratories and production sites.
- Scalability: Compatible with research and GMP-grade hPSC lines for scalable cell supply.
Translational & Preclinical Research
- Scientific Value: Cells exhibit primary hepatocyte-like phenotype and function, improving disease model fidelity.
- Operational Value: Defined system reduces lot-to-lot variation, supporting IND-enabling studies.
- Translational Continuity: Bridges stem cell differentiation to preclinical validation of liver-targeted therapeutics.
Pipeline & Workflow Integration
This method fits within the discovery-to-preclinical continuum by providing a scalable source of functional hepatocytes for downstream applications.
- Discovery Biology: Supports hypothesis testing in liver biology using reproducible, defined differentiation.
- Screening: Enables standardized hepatocyte-like cell production for consistent compound evaluation.
- Analytics: Generates quantifiable functional readouts (e.g., albumin, urea) for comparative condition analysis.
- Translational Research: Provides continuity from differentiation to preclinical models of liver disease and drug response.
- Enterprise Reuse: Defined, scalable platform supports reuse across projects and sites, reducing re-optimization burden.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in hepatocyte function reduces mechanistic ambiguity in liver-related assays.
- Operational Value: Defined components and serum-free process enhance reproducibility and scalability.
- Strategic Value: Enables better go/no-go decisions by reducing biological variability in preclinical data.
- Portfolio Impact: Risk-adjusted prioritization of liver-targeted candidates through reliable model systems.
Implementation Considerations
- Expertise in stem cell culture and differentiation protocols.
- Access to recombinant laminin matrices and defined differentiation media.
- Standardization of coating and incubation procedures across teams.
- Adaptation considerations for different hPSC lines and scale-up formats.
- Limitations include functional maturation compared to primary hepatocytes, as noted in source.
